

COPY OF PAPERS ORIGINALLY FILED

AMENDMENT

RECEIVED

MAR 0 5 2002

TECH CENTER 1600/2900

Replace the paragraph on page 10, line 26 to page 11, line 3, with the following:


A is $-W_i$ -COX_jY wherein Y is COR² or an isostere thereof and R² is a noninterfering substituent. Each of W and X is a spacer and may be, for example, optionally substituted alkylene, alkenylene, or alkynylene, each of i and j is 0 or 1. Preferably, W and X are unsubstituted. Preferably, j is 0 so that the two carbonyl groups are adjacent to each other. Preferably, also, i is 0 so that the proximal CO is adjacent the ring. However, compounds wherein the proximal CO is spaced from the ring can readily be prepared by selective reduction of an initially glyoxal substituted β ring. In the most preferred embodiments of the invention, the α/β ring system is an indole containing CA in position 3- and wherein A is COCOR².

In the Claims:

Please replace presently pending claim 1 with the following claim 1:

1. (Twice amended) A compound of the formula:





and the pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof, wherein

represents a single or double bond;

one Z² is CA or CR⁸A and the other is CR¹, CR¹₂, NR⁶ or N wherein each R¹, R⁶ and R⁸ is independently hydrogen or noninterfering substituent;

A is $-W_i$ -COX_jY wherein Y is COR² or an isostere thereof and R² is hydrogen or a noninterfering substituent, each of W and X is a spacer of 2-6Å which is substituted or unsubstituted alkylene, alkenylene or alkynylene, and each of i and j is independently 0 or 1;

R⁷ is H or is optionally substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroalkyl, heteroalkyl, heteroalkynyl, heteroalkynyl, heteroalkylaryl, or is SOR, SO₂R, RCO,